COVID-19 Health System Response Monitor (HSRM)

The COVID-19 Health Systems Response Monitor (HSRM) contains information on how countries’ health systems responded to the pandemic between 2020 and early 2022. The Archive of individual country evidence is complemented by cross-country comparative Analyses which synthesise policy responses to key challenges presented by the crisis and point the way to building better-prepared and more resilient health systems.

 

COVID-19 vaccination strategy

16 May 2022 | Country Update

Ordering and delivering

At the beginning of March 2021, three COVID-19 vaccines are available in Belgium: Comirnaty® (Pfizer/BioNtech), Moderna® and AstraZeneca® vaccines.

The vaccination schedule for these three vaccines consists of two doses (only one dose is not recommended by the Belgian Superior health council), administered with a recommended interval of 21 days (that can be extended to maximum 35 days if needed) for Comirnaty®, 28 days for Moderna®, or 12 weeks for AstraZeneca®.

The vaccine of Pfizer/BioNtech (Comirnaty®) is delivered by the firm in hospital hubs. Hospital hubs were designed by the Federal Agency for Medicines and health Products (FAMHP) and must be equipped with Ultra temperature (ULT) freezers. Maximum quantities that can be delivered (quotas) in each hub is defined by the Federal State, according the number of vaccines available. These quotas are communicated by the FAMHP. Other vaccines (Moderna® and AstraZeneca®) are delivered by the firms in a central HUB of Medista, a highly specialized medical supply chain company that operates in a strictly controlled environment. Medista was designated by the FAMHP to receive and store vaccines as well as the equipment required for vaccination (syringes, needles, dry ice, etc.).

Under the supervision of the FAMHP, Medista is also responsible for distributing the vaccines to centres that have vaccine storage facilities, i.e. from the hubs to hospitals, collective care institutions (including nursing homes and homes for the elderly), and vaccination centres.

Based on the number of vaccines available, the federal state communicates to each federated entity their maximum quota of vaccines. Each federated entity is then responsible for distributing this quota between hospitals, collective care institutions and vaccination centres.

The national vaccination plan

The Belgian vaccination strategy consists of three phases:

● Phase 1a (few vaccines and stocks, multi-dose vials, complex storage conditions of frozen vaccines): centralised administration of vaccines to high-priority target groups, according to the following sequence:
○ Residents and staff (including volunteers) in nursing homes and homes for the elderly followed by collective care institutions.
○ Health care professionals working in hospitals and health care and support professionals working in ambulatory care.
○ Other hospital professionals and health professionals working in other health services such as in preventive programmes.

● Phase 1b (wider range of vaccines and stocks, multi-dose vials, less complex storage conditions): centralised administration of vaccination extended to:
○ People aged 65 years and over, either indistinctly or by descending age categories depending on the availability of vaccines (decision managed by the federated entities).
○ People aged 45-64 years old with a well-known risk factor, later extended to 18-64 years for some co-morbidities.
○ People occupying a critical function within an essential social or economic profession (criteria not yet defined).
○ Pregnant women, as signalled by the professionals in charge of pregnancy follow-up

● Phase 2 (very wide range of vaccines and stocks, both multi-dose and single dose vials, simple storage in the fridge): vaccination generalised to all adults (18 years and over), including low-risk groups, via both centralised and decentralised channels. The vaccination prioritisation is done on the basis of age. Also, people living in community based establishements (e.g. prisons) are prioritized.

The timeline is currently as follows:
• Residents of nursing homes and staff of nursing homes : Starting January 2021 (with a pilot phase that started on 28 December2020)
• Hospital health care professionals: starting end of January 2021
• First line health care professionals: starting February 2021
• Collective health care facilities and other hospital personnel starting February 2021
• Over 65 years of age: starting March 2021
• 18/45-64 years old with comorbidities : starting March 2021
• People with critical functions in essential sectors: starting April 2021
• General population: starting June 2021

Also from April 2021, Belgians that are willing to get vaccinated, but do not fulfil the phase’s vaccination criteria, can access an online platform (Qvax for Wallonia and Flanders, Bruvax for the Brussels region) to sign up to receive leftover vaccine doses from vaccination centres. Priority in this system is given to older people.

Invitation process

Vaccination is done on a voluntary basis and is free. Belgian federated entities are responsible for initiating the vaccination process in respect with this national vaccination plan.

A computerized centralized booking system is in place since February 15th 2021. The sending of invitations is initiated from the booking application, which creates a vaccination code. An activated vaccination code that has not yet resulted in the registration of one or more vaccination moments remains valid until 31 December 2021.

Individual invitations can be sent by post, text message and/or email. The invitation includes a link toward the booking application and a phone number for people unable to use the online booking application, as well as general and organizational information. People are also invited to contact their GPs, pharmacists, or a call centre managed by the federated entities in case of questions. People have then the option to confirm, refuse or move their appointment, either online via the centralized booking system or by phone. The appointment for the second dose is made at the same time.

The selection of individuals and the procurement of contact information is done using different sources, such as the national register (e.g. for people aged 65 years and over), sickness funds data (e.g. for people with risked co-morbidities) or the Common Base Registry for HealthCare Actor (CoBRHA) (e.g. for health care workers).

Responsibility to sign up to the Qvax or Bruvax platforms (see the section on vaccination timeline) is on the citizen’s own initiative.

Vaccines administration

The vaccination effort in phases 1a and 1b is centralized. Vaccines are delivered in hospitals for hospital staff, in collective care facilities (e.g. in nursing homes and homes for older people) for both residents and staff (including volunteer), and in vaccination centres for other people. People tasked to administer the vaccine are those allowed to do so under Belgian law, this may include besides health care providers also trainees, students, pensioners, volunteers, and other profiles. These people are allowed to provide vaccination following the law of 6th November 2020 (see also section 2.2). This law allowed, in the context of the COVID-19 pandemic, people without valid professional titles to perform nursing acts (including vaccine administration) under strict conditions, including having had prior training. This training is to be provided by a nurse or doctor, both in relation to the nursing activities performed and to health protection measures necessary to perform these nursing activities. The training must be adapted according to the knowledge and skills of people following them. The nursing activities must then be carried out under the supervision of the nurse coordinator, who must be accessible. This does not require the physical presence of the nurse coordinator.

Supplies to address adverse events during vaccination are provided by the place where the vaccination is done (vaccination centres, hospitals, collective care facilities).

To speed up vaccination, an increase in the number of vaccination centres is planned. The number/brand of vaccines available will also be increased (e.g. with the Johnson & Johnson vaccine). Moreover, when logistical obstacles will be reduced (i.e. very wide range of vaccines and stocks, both multi-dose and single dose vials, simple storage in the fridge), vaccination will probably also be allowed in GPs office or other decentralized centres (discussions ongoing).

Federated entities also plan to provide for "mobile actors" capable of reaching populations that are not able to go to a vaccination centre on their own (see below: access).

In May 2022, some pilot tests for vaccination in pharmacy were launched.

Vaccination financing, coverage and access

The financing of vaccination is shared between federated entities and the federal state/compulsory health insurance. The operation of large-scale vaccination centres involves the mobilization of many people with different backgrounds. These may include trainees, students, pensioners, health care providers and other volunteers, these people may be contracted in the following forms:
● on a volunteer basis;
● via an employment contract (e.g. ordinary or student work);
● via a provision of their employer (who therefore continues to pay the person);
● via self-employed workers.

Anyone aged 18 and over with a social security identification number (SIN) has access to the vaccine free of charge (no cost-sharing). This includes all persons residing in Belgium (the NISS corresponds to the national register number) or persons not residing in Belgium but having close and stable relations with Belgium, such as cross-border workers (these persons are identified by a BIS number). Some of these persons do not yet have a BIS number (e.g. because they had not yet needed one). In this case, the vaccinating doctor or a social secretariat can create a BIS number directly (but only if the patient presents a valid identity document with predefined minimum identification data).

The vaccination of people who do not meet these criteria (homeless people, undocumented migrants, etc.) is currently under discussion. Federated entities also plan to provide for "mobile actors" capable of reaching populations that are not able to go to a vaccination centre on their own. Two populations are particularly targeted: 
● people who are bedridden and cannot move or be moved in acceptable conditions (home vaccination);
● people in precarious situations that prevent them from going to vaccination centers for various reasons (vaccination directly with these people in the field or in collective facilities such as day/night shelters for homeless people).

Vaccination surveillance

A single software package, Vaccinnet+, is used to record all vaccinated people and allow all required activities related to surveillance and pharmaco-vigilance. People in charge of the vaccination are responsible for the uploading of data on vaccinated individuals on Vaccinnet, including information about the received vaccine (brand, lot number, date of vaccination, etc).

Sciensano is charged with the vaccine surveillance plan. In order to achieve post authorization monitoring and surveillance, COVID-19 testing data are coupled with the COVID-19 vaccine registry Vaccinnet, in addition to other national datasets.

The surveillance plan includes:

• National vaccine uptake and coverage: by vaccine brand, age, gender, geographical region, target group (Health Care Worker, >65y, 18/45-64y and co-morbidities, nursing-home residents), and by socio-economic indicators.
• Identification of breakthrough cases: i.e. Covid-19 confirmed cases occurring in fully vaccinated individuals. Primary objective: Incidence rates of break-through cases: by vaccine-brand, by age, gender, target group, by time since vaccination, by severity. Secondary objective: Conservation of samples of breakthrough cases for ulterior whole genome sequencing (identification of mutations).
• Vaccine effectiveness: the primary objective is to measure pandemic COVID-19 vaccine-effectiveness (CVE) against laboratory confirmed SARS-CoV-2 in patients of all ages, by vaccine-brand. The secondary objective is to estimate pandemic CVE against laboratory confirmed SARS-CoV-2: by target group (Health Care Worker, >65y, 18/45-64y and co-morbidities), by age-group, by gender, by risk-group (ex by specific co-morbidities), by time since vaccination and regularly over calendar time, by vaccine-dose (one vs two dose) if applicable, and by specific genetic variant, if feasible and documented.
• Vaccine safety in support of the FAMHP. The FAMHP regularly publish pharmaco-vigilance data on adverse reactions, both for the public and health professionals.

Vaccination of health care professionals

In May 2022, the compulsory vaccination of health care professionals against COVID-19 is under discussion within the Parliament and has raised extensive discussions between the current political majority and the opposition. The proposal currently supported by the political majority is to impose compulsory vaccination on all health care professionals, but to allow for flexible entry into force, decided by the Council of Ministers, depending on the pandemic situation. This decision should be supported by scientific opinions, in particular from the Vaccination Taskforce and the Superior Health Council.

 

Country

Subscribe to our newsletter

Sign Up